Free Newsletter
New advances made in gene therapy for HIV
An early-stage trial has provided some important proof that gene therapy could be an effective way to fight HIV. Taking five patients who had already failed to respond to standard therapies, the researchers removed immune cells from each of the participants and injected modified lentivirus in each, changing the genetic code of the DNA of the cell so it can fight HIV and prevent the infection from spreading. In Phase II, a larger number of volunteers with HIV will get more than one infusion of the modulated cells. The scientists, led by Dr. Carl June, found that one of the volunteers responded with a significant reduction in the virus while immune cells multiplied and the immune system strengthened in the other four. The fact that they can introduce genes into cells without toxicity or provoking cancer, as has happened in earlier trials, is exactly the kind of proof of concept that gene therapy experts have been working toward.
- read the Washington Post report on gene therapy
Comments
Will this technology really increase the immune cell count without inducing an auto immune disease or a cancer???This has to be addressed before the actual clinical trials....
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




